Introduction
The discovery of Campylobacter pyloridis and its association with gastritis and peptic ulcer disease has become well established within the last few years. The organism is relatively easy to isolate from biopsy material obtained at endoscopy. Several aspects of the organism's physiology and ability to cause disease have been determined and clinical trials comparing differing treatments are now being conducted.
Historical perspective
Since the turn of the century, curved or spiral bacteria have been reported from human gastric specimens by several workers."2,3 However, it was not until 1975 when Steer & Colin-Jones observed Gram-negative bacteria on the gastric mucosa of 80% oftheir patients with gastric ulcers,4 that the presence of these organisms was considered possibly associated with active gastritis. In 1979, Warren described campylobacterlike organisms on nearly all gastric mucosal biopsies that he received,5 most of which showed histological changes of active chronic gastritis, i.e., infiltration with neutrophils, lymphocytes and plasma cells. This led Warren & Marshall to perform clinical studies of patients requiring gastroscopy for various symptoms and diseases. They found that curved bacteria were present in virtually all patients and that in 95% of these, there was histological evidence of active chronic gastritis.6 A further prospective study demonstrated the presence of the bacteria in 70% and 90% of gastric ulcer and duodenal ulcer patients respectively.7 By this time the curved bacterium had been successfully isolated as a Gram-negative, microaerophilic organism which has since achieved official recognition as Campylobacter pyloridis. 
Campylobacterpyloridis, gastritis and peptic ulcer
The source of C. pyloridis infection is unknown. Curved bacteria colonise the gut of several animals'5 but despite lengthy search, they have not been found in other parts of the human alimentary tract.'6 How does the organism cause gastritis? C. pyloridis is now known to belong to a group of bacteria that can adapt to a mucus environment. Their corkscrew movement enables them to penetrate and pass freely in viscous solutions which other bacteria such as Escherichia coli find restrictive.'7 Having penetrated gastric mucus and under the influence of chemotactic stimuli, they move towards the gastric epithelium and in particular to intercellular junctions between gastric epithelial cells where the highest concentration of potential nutrients/growth factors such as urea and haemin diffuse out. C. pyloridis produces a large amount of urease (estimated to be 1000 times greater than Proteus vulgaris'8) which splits the urea to produce ammonia with a subsequent increase in local pH that also promotes multiplication of the organism. C. pyloridis attracts and activates neutrophils;'9 this may occur via an action on local complement components by the bacterium leading to the release of substances chemotactic to leucocytes.20 Inflammation and gastritis result with the following histological and pathophysiological changes:2' (a) adherence pedestals bet-How may C. pyloridis infection further progress to peptic ulceration? In some patients, for reasons not fully understood, acute infection by the organism is not cleared by normal immune mechanisms leading to a chronic phase. 22 The rapid hydrolysis of urea results in the formation of ammonia which causes coupling of hydrogen ions to form ammonium ions producing hypoacidity and secondly, a direct toxic affect on the gastric mucosa via depletion of ATP.'8 These events together with disruption of mucus production predispose to ulcer formation when acid and other luminal factors such as pepsin reach the damaged mucosa.
Antibody response and measurement
Antibody production against C. pyloridis has been studied by several groups. Serum complement fixation, haemagglutination and bacterial agglutination tests have all been reported with raised titres found in bacteria positive patients. 23 Enzyme linked immunosorbent assay (ELISA) techniques recently developed have also shown significantly raised serum IgG and IgA titres to C. pyloridis.24 In this journal, Sethi et al. demonstrate the presence of antibodies by both complement fixation and ELISA techniques.'4 In those patients with histological evidence of gastritis, 77% had significant titres of antibody to the organism whereas all those with normal histology failed to show a raised antibody level. Although circulating IgG antibodies are necessary in preventing systemic invasion, it is local secretory IgA levels which are more important for mucosal surface immunity. An ELISA method has also been used to show detectable titres of IgA to C. pyloridis in the gastric juices ofpatients with gastritis.2" These antibodies do not eliminate the infection or prevent colonisation but they may lessen bacterial adherence and invasion.
Diagnosis of C. pyloridis infection
How is C. pyloridis infection diagnosed? The organism can be detected in fixed sections of biopsy material through different staining processes. Routine haematoxylin and eosin will stain any bacteria present but a silver stain such as Warthin-Starry is superior.5 Other techniques used include phase contrast microscopy, fluorescent labelling with acridine-orange and a modified Giemsa stain, the latter giving an especially rapid, simple and reliable result.26 A polyclonal antibody raised in rabbits has also been used to label C. pyloridis in tissue sections27 and electron microscopy has been particularly helpful in illustrating the organism's ultrastructure and its relationship to the gastric mucosa. 28 The In vivo effect of anti-ulcer drugs It has been known for some time that gastric acid is the major precipitating cause of peptic ulceration and that inflammation and in particular active chronic gastritis produces the initial pathological changes which allow subsequent damage by acid.38 '39 The inhibition of acid production by either histamine-2 (H2) receptor antagonists or proton pump inhibitors, though producing ulcer healing, does not remove either the inflammation' or the colonization with C. pyloridis. 
Conclusions
The last case report is but one example of the extremely strong evidence which has built up for the association of C. pyloridis with gastritis and peptic ulcer disease. However, C. pyloridis is only one of a number of factors which have received much attention and investigation in this field recently. Prostaglandins for example have been shown to exert several different mucosal protective effects including inhibition of acid secretion and increasing bicarbonate secretion. 48 Further research lies ahead in order to determine more clearly how C. pyloridis causes disease and which forms of treatment will give the best results. In a recent popular publication, the following passage appeared:
'Peptic ulcer is a chronic relapsing disorder. Medical therapy does not alter the underlying ulcer diathesis and only an effective acid-reducing operation cures peptic ulcer disease.'49 It seems therefore that there is still some way to go to fully prove the role of C. pyloridis in upper gastrointestinal disease and perhaps this should be the main aim for the near future.
